Abiopharma

Unhappy With The $35.00 Per Share Buyout Price? Contact Kaskela Law to Discuss Your Legal Rights and Options with Respect to the Buyout - DSGR

Arbe to Present at Canaccord Genuitys 46th Annual Growth Conference

Neuronetics and Jorey Chernett Announce Shared Vision

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Letter to Surf Air Mobility Inc. Shareholders from Chairman of the Board

CrowdStrike Fal.Con 2026 Sells Out at Record Pace as the Industry Races to Secure AI

The Oncology Institute Rebrands as Starling Oncology

Ginkgo Bioworks and Acies Bio Partner to Expand Global Access to High-Performance Aspergillus niger Strains for Protein Production

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

Archer’s Midnight Completes City-to-City Flights in California Ahead of White House’s eIPP

From AI Prompts to Perfect Property Placement: Phillips Edison & Company Makes Site Selection Smarter

VirTra Sets Second Quarter 2026 Conference Call for Thursday, August 13, 2026 at 4:30 p.m. ET

Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call

Griffon Corporation Announces Closing of AMES Australasia Transaction